Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Abstract

Author contributions: Meng W and Zhu HH contributed equally to this work; Meng W conducted the study, data collection, management and analysis, and drafted the manuscript; Zhu HH did data correction, designed the analysis strategy and did data interpretation, co-drafted and revised the manuscript, reviewed and edited the whole manuscript; Xu ZF performed quality control on ELISA work; Cai SR performed previous screening work and collection of serum samples; Dong Q performed helpful work in previous screening; Pan QR did part of ELISA work; Zheng S co-supervised the field activities and designed the study's analytical strategy; Zhang SZ co-designed the study, co-supervised the field activities and did quality assurance and control. METHODS:We conducted a molecular epidemiology study in Hangzhou, China, from year 2006 to year 2008. Serum samples were collected from 93 CRC, 41 advanced adenomas, 137 adenomas, 47 non-adenomatous polyps, and 158 normal participants in a community setting. Serum M2-PK and carcinoembryonic antigen (CEA) were measured using Enzyme-linked immunosorbent assay. SPSS 16.0 software was used to perform data analysis. Area under the receiver operating characteristic curve (AUC), sensitivity, and specificities were estimated for serum M2-PK in diagnosis of colorectal lesions and compared with CEA. RESULTS:Average serum M2-PK value among 158 normal people was 2.96 U/mL and not affected by gender (P = 0.47) or age (P = 0.59). Average serum M2-PK (U/mL) was 14.75 among stage Ⅲ and 13.10 among stage Ⅰ and Ⅱ CRC patients, about 4 times higher than that among normal people. Average serum M2-PK was 8.58, 6.70, 5.13 and 2.51 U/mL among advanced adenoma, adenomas, non-adenomatous polyps, and inflammatory bowel disease patients, respectively. AUC for serum M2-PK was greater than that for CEA among all colorectal lesions. AUC for serum M2-PK was 0.89 (0.84, 0.94) (95% confidence interval), higher than that for CEA [0.70 (0.62-0.79 The diagnostic sensitivity for all colorectal lesions increased with decrease in the cut-off value of serum M2-PK. The diagnostic sensitivity (%) of serum M2-PK was 100.00 for CRC, 95.12 advanced adenoma, 82.48 adenoma, and 82.98 non-adenomatous polyp. There were no CRC cases missed and 40.51% of BRIEF ARTICLE

A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer

“…However, there appears to be some contention in the literature regarding its utility. Some studies on faecal M2-PK have shown a favorable sensitivity and specificity for colorectal cancer and adenoma [ 8 , 9 ] whilst other studies have shown an unfavorable sensitivity and specificity of faecal M2-PK [ 10 - 12 ].…”

Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer

“…Many reports in the literature have firmly established a link between PKM2 expression levels and various cancers, by IHC, biofluid and MS based analyses [65][66][67]. The synergy with CRC is also well documented [68][69][70], including elevated levels detected in patient faecal specimens [71,72]. Pyruvate kinase catalyzes the last step in the process of glycolysis (rate-limiting), transfer of a high-energy phosphate group from phosphoenolpyruvate (PEP) to ADP, producing ATP and pyruvate.…”

Использование Спектральной Эллипсометрии И Спектроскопии Комбинационного Рассеяния Света В Скрининговой Диагностике Колоректального Рака

“…Диагностическая чувствительность детектирования для определения отличия больных КРР от здоровых лиц составила ∼ 98%, что согласуется с результатами исследования [17] и превышает чувствительность методов колоноскопии, исследования кала на скрытую кровь, определения раково-эмбрионального антигена, фекальной М2-ПК [18,19].…”